11 – 16 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2010
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
- 2008
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
(
- Contribution to journal › Published meeting abstract
- « previous
- 1
- 2
- next »